Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
08/11/2022 - 08:00 AM
NASHVILLE, Tenn. --(BUSINESS WIRE)--
Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced that Mark L. Baum , Chief Executive Officer, and Andrew Boll , Chief Financial Officer, will participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference to be held on August 17, 2022 .
Harrow Health’s pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com , beginning at 7:00 a.m. ET on Wednesday, August 17, 2022 , and will remain archived there for approximately 90 days. Harrow Health’s management team will be participating in one-on-one meetings during the conference. Interested investors can request meetings exclusively via H. C. Wainwright .
About Harrow Health
Harrow Health, Inc. (Nasdaq: HROW) is an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable. For more information about Harrow Health , please visit the Investors section of the corporate website, harrowinc.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220811005152/en/
Jamie Webb
jwebb@harrowinc.com
Source: Harrow Health, Inc.
HROW Rankings
#1113 Ranked by Stock Gains
HROW Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About HROW
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
